A highly diverse team imagining the undiscovered

RENAL RESEARCH INSTITUTE

Transforming
patient care
through data-driven
innovation

ABOUT THE RENAL RESEARCH INSTITUTE

The heart of RRI’s capacity for innovation is our ability to examine complex problems through multiple lenses.

The Renal Research Institute (RRI) is an internationally recognized incubator of ideas, treatment processes, and technologies to improve the lives of kidney patients. RRI’s leadership in data analytics, computational biomedicine and AI, as well as our access to a large patient population, accelerates the pace of scientific discoveries and their translation into applied medicine. Our team includes some of the brightest minds from around the world, who, along with their disciplinary expertise, bring a deep understanding of global healthcare issues and challenges.

 

Our Research

We operate at the intersection of clinical data, machine data, and real-world practice, with access to a large patient population and one of the world's largest and richest renal datasets. Our deep connection to the scientific community and to med-tech innovators gives us the rare ability to translate insight into action—quickly, precisely, and meaningfully.

 

Latest Research & News

Latest Research

  • John Danziger, Joanna Willetts, John Larkin, Sheetal Chaudhuri, Kenneth J Mukamal, Len A Usvyat, Robert Kossmann

    RESULTSAmong 6404 patients with incident kidney failure (male, 4182 [65%]; mean [SD] age, 57 [14] years) followed up for the first 90 days of dialysis therapy, 12% (n = 742) had measurable lead in household drinking water. A higher category of household lead contamination was associated with 15% (odds ratio [OR], 1.15 [95% CI, 1.04-1.27]) higher risk of maximum monthly ESA dosing, 4.5 (95% CI, 0.8-8.2) μg higher monthly ESA dose, and a 0.48% (95% CI, 0.002%-0.96%) higher monthly resistance index. Among patients with pre-kidney failure hemoglobin measures (n = 2648), a higher household lead categorization was associated with a 0.12 (95% CI, -0.23 to -0.002) g/dL lower hemoglobin concentration, particularly among those with concurrent iron deficiency (multiplicative interaction, P = .07), among whom hemoglobin concentrations were 0.25 (95% CI, -0.47 to -0.04) g/dL lower.OBJECTIVETo examine whether commonly encountered levels of lead in household water are associated with hematologic toxicity among individuals with advanced kidney disease, a group known to have disproportionate susceptibility to environmental toxicants.DESIGN, SETTING, AND PARTICIPANTSCross-sectional analysis of household water lead concentrations and hematologic outcomes was performed among patients beginning dialysis at a Fresenius Medical Care outpatient facility between January 1, 2017, and December 20, 2021. Data analysis was performed from April 1 to August 15, 2023.CONCLUSIONThe findings of this study suggest that levels of lead found commonly in US drinking water may be associated with lead poisoning among susceptible individuals.IMPORTANCEThe consequences of low levels of environmental lead exposure, as found commonly in US household water, have not been established.MAIN OUTCOMES AND MEASURESHematologic toxic effects were defined by monthly erythropoiesis-stimulating agent (ESA) dosing during the first 90 days of incident kidney failure care and examined as 3 primary outcomes: a proportion receiving maximum or higher dosing, continuously, and by a resistance index that normalized to body weight and hemoglobin concentrations. Secondarily, hemoglobin concentrations for patients with data prior to kidney failure onset were examined, overall and among those with concurrent iron deficiency, thought to increase gastrointestinal absorption of ingested lead.EXPOSUREConcentrations of lead in household water were examined in categorical proportions of the Environmental Protection Agency's allowable threshold (15 μg/L) and continuously.

No Results Found

Latest News

No Results Found

Program

LATEST EPISODE

Beyond the Equation | Dr. Amaka Eneanya on Kidney Function, Clinical Change, and Communication

March 2, 2026

In this episode of Frontiers in Kidney Medicine and Biointelligence, host Len Usvyat, MD, is joined by Amaka Eneanya, MD, MPH, FASN, Adjunct Professor of Medicine at Emory University School of Medicine and former Chief Transformation Officer at Emory Healthcare. Dr. Eneanya reflects on kidney function estimation, the evolution of clinical tools in nephrology, and the role of communication, patient perspectives, and digital platforms in shaping medical discourse. This episode offers an in-depth discussion on how research findings move from theory into real-world clinical practice.